Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Shuntaro Ikegawa, Adam S. Sperling, Michela Ansuinelli, Sarah Nikiforow, David Quinn, Dexiu Bu, Jennifer Mataraza, David Pearson, Lawrence Rispoli, Marc A Credi, Nina Orwitz, Yohei Arihara, Rao Prabhala, Lakshmi Bhavani Potluri, Carol Reynolds, Serena De Vita, Nikhil C Munshi, Jerome Ritz

Blood (2023) 142 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2023-177721

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Sarah Nikiforow, Mitchell Horwitz, John M. McCarty, Anum Abbas, James M. Coghill, Jenny Stanton, Julie Ma, Spyridoula Vasileiou, Sarah Gilmore, Bhagirathbhai Dholaria, Rabi Hanna, Randy Taplitz, Rajat Bansal

Blood (2023) 142 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2023-189708

Published: 2023

Journal Articles

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Blood (2023) 142 (Supplement 1): 6850.

https://doi.org/10.1182/blood-2023-178362

Published: 2023

Journal Articles

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2023) 141 (24): 2932–2943.

https://doi.org/10.1182/blood.2022019107

Published: 2023

Includes: Supplemental data

Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini

Blood (2022) 140 (Supplement 1): 7512–7515.

https://doi.org/10.1182/blood-2022-155603

Published: 2022

Journal Articles

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lauren S Jiménez-Kurlander, Gerald Behr, Nancy J Bunin, Ekaterina Doubrovina, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Leo Mascarenhas, Sarah Nikiforow, Richard J O'Reilly, Anita Price, Barry Shulkin, Ashok Srinivasan, Stephanie Suser, Justin Wahlstrom, Baodong Xing, Susan Prockop

Blood (2022) 140 (Supplement 1): 7524–7526.

https://doi.org/10.1182/blood-2022-157765

Published: 2022

Journal Articles

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Blood (2022) 140 (Supplement 1): 917–919.

https://doi.org/10.1182/blood-2022-157611

Published: 2022

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd

Katie Maurer, Haesook T. Kim, Heather Garrity, Carol Reynolds, Deborah Liney, Augustine Weber, Joseph H. Antin, Corey Cutler, Jerome Ritz, John Koreth, Roman M. Shapiro, Rizwan Romee, Vincent Ho, Mahasweta Gooptu, Catherine J. Wu, Sarah Nikiforow, Robert J. Soiffer

Blood (2022) 140 (Supplement 1): 4804–4805.

https://doi.org/10.1182/blood-2022-162663

Published: 2022

Journal Articles

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Blood (2022) 139 (7): 1098–1110.

https://doi.org/10.1182/blood.2021012764

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Blood (2021) 138 (Supplement 1): 264.

https://doi.org/10.1182/blood-2021-148343

Published: 2021

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Blood (2021) 138 (Supplement 1): 3880.

https://doi.org/10.1182/blood-2021-148652

Published: 2021

Journal Articles

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Blood (2021) 138 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2021-146646

Published: 2021

NARROW

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only